Skip to main content
Premium Trial:

Request an Annual Quote

Power3 Buys Rozetta-Cell

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Power3 Medical Products today announced a definitive agreement to acquire all the stock of stem cell firm Rozetta-Cell Life Sciences.

Upon completion of the deal, expected in October or November, Rozetta-Cell will be merged with Power3 and take its name.

Terms of the deal were not disclosed.

Rozetta-Cell focuses on the delivery and imaging of stem cells during therapy. In a statement, Ira Goldknopf, president and CEO of Power3, said that the acquisition will strengthen his firm's IP portfolio "in a major growth market by merging regenerative medicine with the technologies that we are using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs."

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.